Attenuated vaccines |
Produced from pathogenic isolates via serial passage in embryonated, specific, pathogen-free eggs |
Cause a strong immune response; long-lasting immune response; can survive the low-pH enzymatic environment of the stomach |
Risk of toxic recovery in immunocompromised individuals; low safety profile |
[3,4] |
Inactivated vaccines |
Formaldehyde inactivates live virus production |
Compared with live attenuated vaccines, the safety is improved, and the production process is mature |
Weak immune response; short duration; destruction or alteration of antigens; high cost; multiple vaccinations required |
[4] |
Subunit vaccines |
Antigenic proteins from pathogens |
High safety; modulated immune response; clear target antigen |
Low immunogenicity |
[4,5,6,7] |
DNA vaccines |
Transfection of DNA encoding a certain antigenic protein into animal cells |
Simple to build; easy to mass-produce; high security and high stability |
Cannot be used in humans; naked-pelleted DNA has low immunogenicity |
[8,9,10,11] |
mRNA vaccines |
Transfection of RNA encoding a certain antigenic protein into animal cells |
High transfection rate and simple process |
Unstable; lack of effective delivery vehicles in vivo |
[8,14,15,16,17,18,19] |